Global cardiovascular and renal outcomes of reduced GFR

On behalf of the Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, and Global Burden of Disease Genitourinary Expert Group

Research output: Contribution to journalArticle

Abstract

The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reducedGFRwere calculated by pooled randomeffects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease,GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95%uncertainty interval [95%UI], 2.0 to 2.4million).More than half of these attributable deathswere cardiovascular deaths (1.2million; 95%UI, 1.1 to 1.4million), whereas 0.96million (95%UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.

Original languageEnglish (US)
Pages (from-to)2167-2179
Number of pages13
JournalJournal of the American Society of Nephrology
Volume28
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Kidney
Chronic Kidney Failure
Uncertainty
Cardiovascular Diseases
Quality-Adjusted Life Years
Premature Mortality
Meta-Analysis
Fasting
Body Mass Index
Cholesterol
Glucose
Health

ASJC Scopus subject areas

  • Nephrology

Cite this

On behalf of the Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, and Global Burden of Disease Genitourinary Expert Group (2017). Global cardiovascular and renal outcomes of reduced GFR. Journal of the American Society of Nephrology, 28(7), 2167-2179. https://doi.org/10.1681/ASN.2016050562

Global cardiovascular and renal outcomes of reduced GFR. / On behalf of the Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, and Global Burden of Disease Genitourinary Expert Group.

In: Journal of the American Society of Nephrology, Vol. 28, No. 7, 01.07.2017, p. 2167-2179.

Research output: Contribution to journalArticle

On behalf of the Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, and Global Burden of Disease Genitourinary Expert Group 2017, 'Global cardiovascular and renal outcomes of reduced GFR', Journal of the American Society of Nephrology, vol. 28, no. 7, pp. 2167-2179. https://doi.org/10.1681/ASN.2016050562
On behalf of the Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, and Global Burden of Disease Genitourinary Expert Group. Global cardiovascular and renal outcomes of reduced GFR. Journal of the American Society of Nephrology. 2017 Jul 1;28(7):2167-2179. https://doi.org/10.1681/ASN.2016050562
On behalf of the Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, and Global Burden of Disease Genitourinary Expert Group. / Global cardiovascular and renal outcomes of reduced GFR. In: Journal of the American Society of Nephrology. 2017 ; Vol. 28, No. 7. pp. 2167-2179.
@article{921a80d8a26743a09cb9f49d89b154aa,
title = "Global cardiovascular and renal outcomes of reduced GFR",
abstract = "The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reducedGFRwere calculated by pooled randomeffects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease,GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4{\%} of deaths worldwide, or 2.2 million deaths (95{\%}uncertainty interval [95{\%}UI], 2.0 to 2.4million).More than half of these attributable deathswere cardiovascular deaths (1.2million; 95{\%}UI, 1.1 to 1.4million), whereas 0.96million (95{\%}UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.",
author = "{On behalf of the Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, and Global Burden of Disease Genitourinary Expert Group} and Bernadette Thomas and Kunihiro Matsushita and Abate, {Kalkidan Hassen} and Ziyad Al-Aly and Johan {\"A}rnl{\"o}v and Kei Asayama and Robert Atkins and Alaa Badawi and Shoshana Ballew and Amitava Banerjee and Lars Barreg{\aa}rd and Elizabeth Barrett-Connor and Sanjay Basu and Bello, {Aminu K.} and Isabela Bensenor and Jaclyn Bergstrom and Boris Bikbov and Christopher Blosser and Hermann Brenner and Carrero, {Juan Jesus} and Steve Chadban and Massimo Cirillo and Monica Cortinovis and Karen Courville and Lalit Dandona and Rakhi Dandona and Kara Estep and Jo{\~a}o Fernandes and Florian Fischer and Caroline Fox and Gansevoort, {Ron T.} and Gona, {Philimon N.} and Gutierrez, {Orlando M.} and Samer Hamidi and Hanson, {Sarah Wulf} and Jonathan Himmelfarb and Jassal, {Simerjot K.} and Jee, {Sun Ha} and Vivekanand Jha and Aida Jimenez-Corona and Jonas, {Jost B.} and Kengne, {Andre Pascal} and Yousef Khader and Khang, {Young Ho} and Kim, {Yun Jin} and Barbara Klein and Ronald Klein and Yoshihiro Kokubo and Dhaval Kolte and Josef Coresh",
year = "2017",
month = "7",
day = "1",
doi = "10.1681/ASN.2016050562",
language = "English (US)",
volume = "28",
pages = "2167--2179",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Global cardiovascular and renal outcomes of reduced GFR

AU - On behalf of the Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, and Global Burden of Disease Genitourinary Expert Group

AU - Thomas, Bernadette

AU - Matsushita, Kunihiro

AU - Abate, Kalkidan Hassen

AU - Al-Aly, Ziyad

AU - Ärnlöv, Johan

AU - Asayama, Kei

AU - Atkins, Robert

AU - Badawi, Alaa

AU - Ballew, Shoshana

AU - Banerjee, Amitava

AU - Barregård, Lars

AU - Barrett-Connor, Elizabeth

AU - Basu, Sanjay

AU - Bello, Aminu K.

AU - Bensenor, Isabela

AU - Bergstrom, Jaclyn

AU - Bikbov, Boris

AU - Blosser, Christopher

AU - Brenner, Hermann

AU - Carrero, Juan Jesus

AU - Chadban, Steve

AU - Cirillo, Massimo

AU - Cortinovis, Monica

AU - Courville, Karen

AU - Dandona, Lalit

AU - Dandona, Rakhi

AU - Estep, Kara

AU - Fernandes, João

AU - Fischer, Florian

AU - Fox, Caroline

AU - Gansevoort, Ron T.

AU - Gona, Philimon N.

AU - Gutierrez, Orlando M.

AU - Hamidi, Samer

AU - Hanson, Sarah Wulf

AU - Himmelfarb, Jonathan

AU - Jassal, Simerjot K.

AU - Jee, Sun Ha

AU - Jha, Vivekanand

AU - Jimenez-Corona, Aida

AU - Jonas, Jost B.

AU - Kengne, Andre Pascal

AU - Khader, Yousef

AU - Khang, Young Ho

AU - Kim, Yun Jin

AU - Klein, Barbara

AU - Klein, Ronald

AU - Kokubo, Yoshihiro

AU - Kolte, Dhaval

AU - Coresh, Josef

PY - 2017/7/1

Y1 - 2017/7/1

N2 - The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reducedGFRwere calculated by pooled randomeffects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease,GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95%uncertainty interval [95%UI], 2.0 to 2.4million).More than half of these attributable deathswere cardiovascular deaths (1.2million; 95%UI, 1.1 to 1.4million), whereas 0.96million (95%UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.

AB - The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reducedGFRwere calculated by pooled randomeffects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease,GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95%uncertainty interval [95%UI], 2.0 to 2.4million).More than half of these attributable deathswere cardiovascular deaths (1.2million; 95%UI, 1.1 to 1.4million), whereas 0.96million (95%UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.

UR - http://www.scopus.com/inward/record.url?scp=85021768228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021768228&partnerID=8YFLogxK

U2 - 10.1681/ASN.2016050562

DO - 10.1681/ASN.2016050562

M3 - Article

C2 - 28408440

AN - SCOPUS:85021768228

VL - 28

SP - 2167

EP - 2179

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 7

ER -